The work of the Quantitative Medicine Program at the Critical Path Institute (C-Path) focuses on the development and innovation of quantitative solutions for drug development and clinical needs. Our goal is to leverage knowledge from a network of experts in industry, academia, non-profit , and regulatory sciences combined with data acquired from multiple sources to develop quantitative methodologies in pharmacometrics, statistics, systems pharmacology, artificial intelligence, and digital data analytics. The solutions developed by QuantMed are often formally reviewed by regulatory agencies as fit-for-purpose in a drug development context. Because QuantMed’s philosophy is one of open science, solutions developed are publicly available as open source platforms. The QuantMed program is highly collaborative, seeking to advance the development of novel treatments for patients with unmet medical needs. The Quantitative Medicine Program is constantly striving to:
- Lead the generation of advance data analytics solutions for C-Path’s programs (public-private-partnerships, consortia and other collaborations).
- Drive innovation in MIDD, through collaborations with key learned societies such as the International Society of Pharmacometrics, the American Society for Clinical Pharmacology and Therapeutics, and others.
- Integrate clinical and data analytical knowledge to provide solutions to optimize the drug development process: Things that we do.
Our mission is to improve population and individual health by transforming drug development through methodological innovation.
Our vision is to become a nationally and internationally recognized program for Model-Informed Drug Development (MIDD).